RESPIROLOGY
Expert Insight View All

The potential new first-line mNSCLC treatment regardless of PD-L1: Durvalumab + tremelimumab + chemotherapy improved survival

Over the past decades, treatment options in advanced non-small cell lung cancer (NSCLC) patients without oncogenic drivers have been limited to cytotoxic chemotherapies with poor survival outcomes.1 Although patients’ overall survival (OS) has been prolonged with the current standard of care (SoC) (i.e. pembrolizumab with or without chemotherapy) in recent years, the clinical outcomes are still suboptimal.2,3 Dual immunotherapy, which brought substantial survival improvements across multiple malignancies such as advanced melanoma, sheds light on the further advance of metastatic NSCLC (without driver mutations) management.4 The combination of nivolumab (NIVO) and ipilimumab (IPI) with or without chemotherapy has demonstrated superior survival benefits in these patients, leading to the regulatory approval from the United States (US) Food and Drug Administration (FDA).5,6 More recently, the efficacy of durvalumab and tremelimumab plus chemotherapy (D + T + CT) in treatment-naïve metastatic NSCLC patients has also been evaluated in the POSEIDON trial.7 In a webinar organized by the Hong Kong Precision Oncology Society, Dr. Melissa L. Johnson presented the encouraging data from POSEIDON and discussed the latest advances of immunotherapy in metastatic NSCLC. Dr. Au, Siu-Kie Joseph also shared his expert insights on the new POSEIDON data and discussed their impacts on the local clinical practice in an interview with Omnihealth Practice.

03 May 2022
thumb

Dr. Melissa L. Johnson

Director,
Lung Cancer Research Program,
Sarah Cannon/Tennessee Oncology PLLC,
Nashville, United States

thumb

Dr. Au, Siu-Kie Joseph

Head and Consultant Clinical Oncologist,
Hong Kong Adventist Hospital Oncology Centre
President,
Hong Kong Lung Cancer Study Group
Hong Kong Precision Oncology Society

Meeting Highlight View All

Defying the odds: Embarking on the new era of personalized immunotherapies for small cell lung cancer subtypes

thumb

Dr. Lauren Averett Byers

Associate Professor,
Department of Thoracic/Head and Neck Medical Oncology,
The University of Texas MD Anderson Cancer Center,
United States

thumb

Dr. Kristin Higgins

Associate Professor,
Department of Radiation Oncology,
Emory University School of Medicine
Medical Director of Radiation Oncology,
The Emory Clinic, United States

Research spotlight View All

Awake prone positioning in the pandemic era: A potential alternative to prevent IMV in patients with respiratory failure

In brief The 18-day single-center experience of awake prone position (APP) in patients admitted to the intensive care unit (ICU) of Pamela Youde Nethersole Eastern Hospital in Hong Kong (PYNEH) with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection demonstrated the effectiveness

28 Jan 2022

Prone positioning in non-intubated patients with coronavirus – A single centre experience

MY Man, SM Lam, HP Shum, KC Li, S Lau, VHL Ip , WW Yan

thumb

Dr. Lam, Sin-Man Grace

Department of Intensive Care,
Pamela Youde Nethersole Eastern Hospital

thumb

Dr. Man, Man-Yee

Department of Intensive Care, Pamela Youde Nethersole Eastern Hospital